UPDATE : Monday, July 13, 2020
Humedix wins patent on new anti-aging material
  • By Jeong Sae-im
  • Published 2019.12.26 14:31
  • Updated 2019.12.27 10:30
  • comments 1

Humedix said it has won a local patent on a new substance called “nicotinamide riboside (NR) derivatives conjugated with fatty alcohol” that has an anti-aging effect, which the company said was for the first time in the world.

Humedix has been searching for new high-performance cosmetic materials, paying attention to the properties of nicotinamide adenine dinucleotide (NAD+) introduced in many studies. The substance helps cellular respiration, produces energy in mitochondria within cells, and regulates the activity of genes that eliminate problems in cells.

The company has tried to develop a new cosmetic material for anti-aging by using the properties of NAD+. It used self-developed conjugation technology to join NR, a precursor of NAD+, with a fatty alcohol. Through the new synthesis study, Humedix developed NR derivatives conjugated with fatty alcohol.

The company obtained a domestic patent on the material to protect its intellectual property rights and registered the material’s name on the list of the International Nomenclature of Cosmetic Ingredients (INCI) and the standardized domestic names of substances. It also is seeking an international patent to own the new materials’ global rights.

Based on the novel derivatives, Humedix plans to develop cosmetics for wrinkle improvement and anti-aging effects from next year and use it as a raw material for medicines and health functional foods as well.

“It is significant that we discovered the world’s first anti-aging substance and acquired the patent with our esthetic expertise and R&D,” Humedix CEO Kim Jin-hwan said. “As the anti-aging effect of NAD+ is attracting attention from major medical research institutions in the world, we will place more focus on developing new materials through various synthetic studies making the most of NAD+.”


<© Korea Biomedical Review, All rights reserved.>

Other articles by Jeong Sae-im
iconMost viewed
Comments 1
Back to Top